From an intensivist's perspective, the main focus in the management of critically ill patients is survival to intensive care unit discharge. However, from a patient's perspective, the most relevant outcome is to return home in an acceptable functional state. For many years, this discrepancy has largely been ignored. Only through the last decade have we begun to understand the detrimental effects of critical illness on long-term survival and healthrelated quality of life (HQoL) [1, 2] . Accordingly, only a small number of multicenter randomized controlled trialshave evaluated the effects of therapeutic interventions on long-term outcomes of critical illness (Table 1) .
Long-term outcome is particularly poor for patients surviving sepsis or septic shock, with 5-year mortality rates reported as high as 60 % [3, 4] . Short-term organ dysfunction and the need for artificial life support have been identified as crucial risk factors for unfavorable long-term outcomes in septic shock survivors [5] . Readmissions due to infectious, cardiovascular or pulmonary complications after an episode of sepsis are frequent and occur early following hospital discharge [6] . One possible cause of adverse long-term outcomes of septic shock is prolonged immunomodulation. Sub-clinical inflammation is a well-known risk factor for cardiovascular and all-cause mortality in non-critically ill patients. It has been hypothesized that critical illness induces a state of prolonged sub-clinical inflammation, thus contributing to impaired long-term survival and functional state [7] . Accordingly, abdominal sepsis has been found to induce and aggravate atherosclerosis in a murine model [8] . This observation aligns nicely with reports that sepsis survivors continued to exhibit elevated levels of inflammatory markers at hospital discharge [9] and have an increased subsequent risk of cardiovascular events. In addition, proteomics and metabolomics are profoundly altered by sepsis and may contribute to chronic organ dysfunction and impaired outcome.
The Transfusion-Requirements In Septic Shock (TRISS) trial [10] was a well-performed multicenter randomized controlled trial comparing a liberal (>9 g/dL) versus a restrictive (>7 g/dL) transfusion trigger in 998 septic shock patients. In this issue of the journal, Ryegard and colleagues present the results of a sub-study of the TRISS trial focusing on survival status and HRQoL at 1 year after randomization [11] . Once again, the authors found no between-group differences in any of these variables. In doing so, they could reject a ≥3 % increased risk of death associated with a restrictive transfusion threshold. The study has several strengths including its focus on long-term outcome and the high methodological quality of the underlying trial. On the other hand, the fact that the power analysis for the original trial was based on 90-day and not 1-year mortality [12] must be seen as a limitation of the present sub-study. As suggested by fairly wide confidence intervals, the patient population may have been too small to detect a significant difference in 1-year survival between study groups. As hemoglobin levels were not documented during the follow-up period, it is furthermore unclear whether different transfusion thresholds also translated into variable recovery patterns from anemia [13] . Chronic anemia could, for example, increase the risk of certain causes of death. Indeed, the authors argue in their discussion that "[…] restrictive No difference between groups transfusion decreased rates of severe infectious complications in hospitalized patients and increased risk of myocardial infarction in patients with cardiovascular disease" [11] . Unfortunately, the causes of death during the 1-year follow-up period were not evaluated. Finally, while almost full datasets were available to determine 1-year survival status in the whole population, around 25-30 % of data were missing for the nested Danish cohort in which HQoL was determined.
The results of the TRISS trial and its latest sub-study clearly suggest that adoption of a restrictive transfusion policy in patients with septic shock is safe, does not result in relevantly worse short-and long-term outcomes, and spares valuable and short-supplied blood products. Although these results may not be extrapolated to nonseptic critically ill patients, the landmark Transfusion Requirements in Critical Care (TRICC) trial showed equivalence of liberal versus restrictive transfusion triggers in a general intensive care population [14] .
What are the implications of these results for future research? Both the TRICC and TRISS trials either excluded or enrolled too few patients particularly vulnerable to anemia, such as those after cardiac surgery, or with acute myocardial ischemia or brain injury [15] . Therefore, future studies still need to elucidate whether application of a restrictive transfusion trigger in critically ill patients with any of these conditions is equally safe. While Ryegard and colleagues could impressively display that the use of a restrictive transfusion threshold does not alter long-term survival and functional outcome of septic shock as compared to a liberal transfusion threshold, this must still be shown for a non-septic critically ill patient population. Given that 'one size fits all' approaches have repeatedly failed to improve the outcome of critically ill patients, future studies should also evaluate whether individual instead of fixed transfusion triggers could improve survival. For general critical care research, we desperately need more observational cohort studies which carefully assess quantitative and qualitative long-term outcomes that allow clinicians and researchers to identify subgroups with increased risks. We further suggest the systematic introduction of long-term survival and HQoL as secondary endpoints in future multicenter trials.
What are optimal long-term outcomes to assess? Is it 1-year survival or HQoL? Evaluation of survival status alone carries the delicate disadvantage that it is a binary variable but does not give any information on HQoL. On the other hand, when using HQoL scores as outcome variables, it is unclear which differences in score results are truly relevant. Other endpoints such as the rate of patients returning home or to their previous place of residency could meaningfully complement long-term outcomes such as those assessed by the TRISS study group. Finally, and most importantly, the ultimate goal of studies in critical care should be to harmonize the intensivists' questions and hypotheses with patient-centered outcomes! Author details 1 
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